Quantcast

Latest Sunitinib Stories

2008-09-09 00:00:26

Campaigners battling for a cancer victim have been told their case is not exceptional enough. Family and friends of Kay Hopkins, from Harriseahead, are fighting for NHS North Staffordshire to provide the kidney cancer drug Sutent, which has not been approved by the National Institute for Health and Clinical Excellence. They argue that Kay's is an exceptional case. Without the drug it is not safe to operate on her kidney tumour. The 70-year-old wife's supporters had written to NHS...

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008. Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT(R) as first-line therapy in patients with metastatic renal cell carcinoma...

2008-09-05 06:00:23

Cancer drug developer Antisoma has started a Phase II study of AS1411 in metastatic renal cell carcinoma. The single-arm trial will enroll around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days for up to two cycles. Efficacy measures in the trial include response rate, time to progression...

2008-09-05 06:00:22

By LYNDSAY MOSS HEALTH CORRESPONDENT PATIENTS should be allowed to pay privately for cancer drugs and still keep their free NHS care in certain cases, the Scottish Government indicated yesterday. So-called co-payments - patients topping up their care with treatments not available on the NHS - have been banned by many Scottish health boards. But the government has now admitted current guidance on the controversial issue is not clear and has agreed to give new advice to the NHS. It...

2008-09-04 03:00:25

London, UK: 04 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II study of AS1411 in metastatic renal cell carcinoma (kidney cancer). The single-arm trial will enrol around 30 patients intolerant to, or having relapsed after, previous treatments including a tyrosine kinase inhibitor (sunitinib or sorafenib). It will evaluate the safety and efficacy of AS1411 monotherapy given at 40 mg/kg/day for four days every 28 days...

2008-08-26 18:00:48

By Emma Brady Midlands cancer patients are being kept in the dark about new treatments that could extend their lives, it was claimed today. One in four myeloma specialists questioned in a survey admitted hiding facts about new treatments that may be tough to obtain on the NHS, citing the main reason was to avoid upsetting or confusing patients. The Myeloma UK poll comes less than three weeks after the National Institute for health and Clinical Excellence (Nice) issued draft guidance...

2008-08-25 09:00:26

Leading UK cancer experts have accused a health watchdog of forcing patients to remortgage their homes to afford treatments freely available in Europe. The group of 26 professors were "dismayed" at guidance issued by the National Institute for Health and Clinical Excellence (Nice) to deny patients four vital kidney cancer drugs on the NHS. They said the decision showed it was time for a "radical change" in how the NHS makes decisions on what treatments are available for cancer sufferers....

2008-08-25 09:00:26

By Nicola Fenwick CANCER experts have accused a health watchdog of forcing patients to remortgage their homes to pay for treatments freely available in Europe. The group of 26 professors are dismayed at guidance issued by the National Institute for Health and Clinical Excellence (Nice) that deny four kidney cancer drugs on the NHS. Earlier this month, Nice said the drugs + Sutent (sunitinib), Avastin (bevacizumab), Nexavar (sorafenib) and Torisel (temsirolimus) ? were not...

2008-08-20 09:00:22

The National Institute for Health and Clinical Excellence, UK has rejected four kidney cancer treatments for use on the National Health Service on grounds that the drugs are not cost effective, according to PharmaTimes. The draft guidance issued by the National Institute for Health and Clinical Excellence (NICE), contends that Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Wyeth's Torisel (temsirolimus) are costly for the treatment of advanced or...

2008-08-18 09:01:01

By Gavin Engelbrecht THE Government?s drugs approval agency warned last night it might not be able to meet a pledge to speed up decision-making on new treatments. Campaigners and patients have criticised Nice ? the National Institute for Health and Clinical Excellence ? over the time it takes to approve lifegiving drugs. Health Secretary Alan Johnson has pledged to bring decision- making on new drugs down from an average length of two years to only three months. But Andrew Dillon, the...


Word of the Day
endocarp
  • The hard inner (usually woody) layer of the pericarp of some fruits (as peaches or plums or cherries or olives) that contains the seed.
This word comes from the Greek 'endon,' in, within, plus the Greek 'kardia,' heart.
Related